Physician profile
Thomas Urice
NPI 1023016169
$23,248.42
in general payments reported to CMS, 2019-2025
32 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,409 · 2020: $4,124 · 2021: $1,748 · 2022: $4,434 · 2023: $4,542 · 2024: $2,232 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,237 · Consulting Fee: $1,980 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,236.50 |
| Consulting Fee | $1,980.00 |
| Education | $317.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,849.38 | 2019-2025 | Adbry, Anzupgo |
| Celgene Corporation | $2,652.42 | 2019-2020 | |
| Galderma Laboratories, L.P. | $2,179.08 | 2019-2025 | Nemluvio, Oracea, Twyneo |
| Novartis Pharmaceuticals Corporation | $2,167.87 | 2019-2025 | |
| Amgen INC. | $1,770.12 | 2019-2025 | Otezla |
| Janssen Biotech, INC. | $1,767.05 | 2019-2025 | Tremfya |
| Genzyme Corporation | $1,575.45 | 2019-2025 | |
| Lilly USA, LLC | $1,311.74 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,018.86 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $1,005.84 | 2019-2025 | Dupixent |
| Pfizer INC. | $796.31 | 2019-2025 | |
| Abbvie INC. | $772.47 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $627.98 | 2019-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $611.98 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $423.18 | 2019-2025 | Cabtreo, Jublia, Siliq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $365.48 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $320.51 | 2023-2025 | Zoryve |
| Almirall LLC | $306.67 | 2019-2023 | Seysara, Klisyri |
| Dermira, INC. | $144.80 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Incyte Corporation | $92.84 | 2021-2023 | Opzelura |
| Sandoz INC. | $91.80 | 2019-2021 | |
| Nabriva Therapeutics, Plc | $63.32 | 2021-2022 | |
| Dermavant Sciences, INC. | $60.00 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.40 | 2023-2024 | Cyltezo |
| Biocon Biologics INC | $26.51 | 2025 | Yesintek |
| Verrica Pharmaceuticals INC. | $26.16 | 2023 | Ycanth |
| Organon LLC | $25.66 | 2025 | Vtama |
| Kyowa Kirin, INC. | $23.50 | 2024 | Poteligeo |
| Aclaris Therapeutics, INC. | $19.40 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.43 | 2022 | |
| Prugen, INC. Pharmaceuticals | $2.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Urice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.